Key result
Emerging biomarkers for inflammation, plaque instability, platelet activation, and ischemia show promise for early ACS diagnosis, though their lack of specificity may require a multi-marker approach.
Why the study?
Do novel biomarkers improve the early diagnosis and risk stratification of patients with acute coronary syndromes presenting within 3 hours of chest pain onset?
Do novel biomarkers improve the early diagnosis and risk stratification of patients with acute coronary syndromes presenting within 3 hours of chest pain onset?
Novel biomarkers reflecting inflammation, plaque instability, platelet activation, and ischemia show promise for early ACS detection, though a multi-marker approach may be necessary to overcome limited specificity.
May support multi-marker strategies for early ACS but should not yet change practice; leaves open need for prospective validation of specificity.
The existing markers for myocardial necrosis, such as cardiac troponin, creatine kinase-MB, and myoglobin are thought to be released into blood following irreversible myocardial necrosis. Thus results of these tests are usually negative for patients with acute coronary syndromes (ACS) who present to the emergency department (ED) within the first 3 hours after the onset of chest pain. Given the need to make early therapeutic and triage decisions, biomarkers that can be used to diagnose and/or risk stratify ACS patients during their initial ED presentation will be important. Active research in this area has identified several classes of biomarkers that show promise for early detection of disease. These include tests for the presence of acute inflammation and infiltration (e.g., high sensitivity-C-reactive protein, myeloperoxidase), plaque instability (e.g., pregnancy-associated plasma protein-A, placental growth factor), platelet activation (e.g., whole blood choline, platelet density, CD40 ligand), and myocardial ischemia (e.g., ischemia modified albumin, free fatty acids, serum choline, and B-type natriuretic peptide). Each of these tests has demonstrated some utility for early diagnosis. However, as most lack specificity for myocardial disease, routine use may require a multi-marker approach.
No takes yet. Share an insight, caveat, or question.
Alan H.B. Wu (2005) conducted a review in Acute coronary syndromes (ACS). Early detection biomarkers was evaluated. Emerging biomarkers for inflammation, plaque instability, platelet activation, and ischemia show promise for early ACS diagnosis, though their lack of specificity may require a multi-marker approach.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: